Overview

Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403

Status:
Terminated

Trial end date:
2013-03-19

Target enrollment:

Participant gender:

Summary

A 3-year open-label trial for patients who previously participated in Trial Hx-CD20-403 and who fulfill the eligibility criteria for this trial (GEN413) . Th e primary purpose of the trial is to evaluate the long-term effectiveness of repeated courses ( a maximum of 9 treatment courses) of ofatumumab in RA patients who previously received ofatumumab or placebo in Trial Hx-CD20-403.

Phase:

Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Antibodies, Monoclonal
Ofatumumab